Compare Northrop Grumman Corporation (NOC) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Natera Inc. Common Stock — how do they compare? Northrop Grumman Corporation trades at $500.56 (market cap $68.39B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Northrop Grumman Corporation is the larger of the two by market cap, and Northrop Grumman Corporation pays a 2.05% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 82 Days and Natera Inc. Common Stock for 0 Days on average.
| NOC | NTRA | |
|---|---|---|
Market Cap | $68.39B | $57.03B |
Volume | 823,323 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $768.02 | $425.64 |
52-Week Low | $473.46 | $179.42 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $82.37B | $56.18B |
Dividend Yield | 2.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $495.69, up 2.2% on the day, amid a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for the last three quarters, with a net income margin of 10.48% and a P/E ratio of 15.3. Recent news highlights a $20 billion Navy fighter contract loss to Boeing, though the company maintains a record backlog and a dividend payout.
The outlook is mixed: analyst consensus is bullish with a $595.69 price target, but technical indicators and recent contract loss pose near-term risks. Long-term growth is supported by defense spending and key programs like the B-21 bomber, though competitive pressures and execution risks remain.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
